Drug Trial Radar · NCT05739435
Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis
Last checked: Nov 19, 2026Latest source record: Jul 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
165
Actual
Start
Jan 17, 2023
Primary completion
Dec 1, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Alumis IncIndustry
- Sponsor type
- Industry
- First posted
- Feb 22, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, open-label extension (OLE) study in patients with plaque psoriasis who have completed their participation in a previous plaque psoriasis study of ESK-001.
Conditions
- Plaque Psoriasis
Interventions
envudeucitinibDrug
Oral tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- To assess the safety and tolerability of long-term ESK-001 treatmentTime frame: Approximately 3 years
Locations
38 sites in 2 countries. Site status is shown where the registry gives one.
Investigator Site # 1029
Birmingham, Alabama
Investigator Site #1001
Phoenix, Arizona
Investigator Site # 1023
Rogers, Arkansas
Investigator Site #1021
Encinitas, California
Investigator Site #1018
Los Angeles, California
Investigator Site #1007
Santa Monica, California
Investigator Site #1002
Sherman Oaks, California
Investigator site # 1030
Fort Lauderdale, Florida
Investigator Site #1025
Hialeah, Florida
Investigator site # 1028
Miami, Florida
Investigator Site # 1013
Tampa, Florida
Investigator Site #1035
Macon, Georgia
Investigator Site #1043
Sandy Springs, Georgia
Investigator Site #1005
Rolling Meadows, Illinois
Investigator Site # 1011
Columbus, Indiana
Investigator Site #1027
South Bend, Indiana
Investigator SIte#1036
Overland Park, Kansas
Investigator Site #1017
Owensboro, Kentucky
Investigator Site #1026
Rockville, Maryland
Investigator Site #1010
Clarkston, Michigan
Investigator Site #1031
New Brighton, Minnesota
Investigator Site #1033
Norman, Oklahoma
Investigator Site #1019
Portland, Oregon
Investigator Site #1022
Philadelphia, Pennsylvania
Investigator Site # 1012
Rapid City, South Dakota
Investigator Site #1015
Houston, Texas
Investigator Site # 1006
San Antonio, Texas
Investigator Site # 1041
South Jordan, Utah
Investigator Site #2001
Edmonton, Alberta, Canada
Investigator Site # 2008
Surrey, British Columbia, Canada
Investigator Site #2003
Winnipeg, Manitoba, Canada
Investigator Site #2006
London, Ontario, Canada
Investigator Site # 2004
Mississauga, Ontario, Canada
Investigator Site # 2007
North Bay, Ontario, Canada
Investigator Site #2005
Oakville, Ontario, Canada
Investigator Site #2009
Toronto, Ontario, Canada
Investigator Site # 2002
Waterloo, Ontario, Canada
Investigator Site # 2010
Québec, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.